Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Shareholding

4 Nov 2008 13:10

RNS Number : 4034H
ReGen Therapeutics PLC
04 November 2008
Β 

ο»Ώ

4thΒ November 2008

REGEN THERAPEUTICS PLCΒ 

("ReGen" or the "Company"; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1.Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

Β 

2.Reason for the notification:

An acquisition or disposal of voting rights

Β 

3.Full name of person(s) subject to the notification obligation (iii):

Andrew Clement Wilson

Β 

4.Full name of shareholder(s) (if difference from 3):

As Above

Β 

5.Date of the transaction and date on which the threshold is crossed or reached (v):

3rdΒ November 2008

Β 

6.Date on which issued notified:

4thΒ November 2008

Β 

7.Threshold(s) that is/are crossed or reached:

13%

Β 

8.Notified detailsΒ 

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code GB00B28XMY25

Situation Previous to the triggering transaction (vi) -

Number of Shares 1,720,000

Number of Voting Rights (viii) 1,720,000

Resulting situation after the triggering transaction (viii) -

Number of Shares 1,870,750

Number of Voting Rights - Direct (x) 1,870,750

Number of Voting Rights - Indirect (xi) N/A

% of voting rights - Direct 13.45

% of voting rights - Indirect N/A

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument N/A

Expiration date (xiii) N/A

Exercise/Conversion Period/Date (xiv) N/A

Number of voting rights that may be acquired if theΒ 

instrument is exercised/converted N/A

% of voting rights N/A

Total (A+B)

Number of voting rights 1,870,750

% of voting rights 13.45

Β 

9.Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):Β Giltspur Nominees Limited-Brewin Dolphin

Proxy Voting:

Β 

10.Name of the proxy holder: N/A

Β 

11.Number of voting rights proxy holder will cease to hold: N/A

Β 

12.Date on which proxy holder will cease to hold voting rights: Β N/A

Β 

13.Additional information: Brewin Dolphin act as

Β  Broker to client

Β 

14.Contact name: Patrick Wilson

Β 

15.Contact telephone number: 028 90 446000

For further information:

For further information, please contact: Percy Lomax ReGen Therapeutics Plc Tel: 020 7153 4920 Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel: 020 7628 3396Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
HOLBIBJTMMMMBFP
Date   Source Headline
28th May 20197:00 amRNS9th Annual LD Micro Invitational
7th May 20197:00 amRNSNotice of AGM
2nd May 20197:00 amRNSDirector/PDMR Shareholding
1st May 20197:00 amRNSUpdate on IND Application
25th Apr 20195:00 pmRNSDirector/PDMR Shareholding
24th Apr 201912:55 pmRNSReissue: Interim Clinical Data
24th Apr 20197:00 amRNSInterim Clinical Data
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
4th Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSIND Application Submitted for NASH Oral Treatment
7th Feb 20197:00 amRNSDirectorate Change
11th Dec 20187:00 amRNSExercise of Warrants & Issue of Equity
3rd Dec 20187:00 amRNSMilciclib HCC Phase IIa Trial Enrollment Completed
28th Nov 20187:00 amRNSForalumab: Phase 1 Trial with Nasal Administration
27th Nov 20187:00 amRNSHolding(s) in Company
26th Nov 20187:00 amRNSStatement re: ADSs
23rd Nov 20185:00 pmRNSClosing of Offering and Total Voting Rights
20th Nov 20187:30 amRNSDiscounted exercise prices of outstanding warrants
20th Nov 20187:00 amRNSOffer Pricing, Nasdaq Listing & Loan Conversion
18th Oct 20187:15 amRNSAmended Registration Statement filed with the SEC
16th Oct 20187:00 amRNSMilciclib synergistic activity presented at AASLD
25th Sep 20187:00 amRNSTiziana announces Offering & Application to Nasdaq
24th Sep 20187:03 amRNSInterim Results for Six Months Ended 30 June 2018
24th Sep 20187:00 amRNSU.S. FDA Approval IND Nasal Foralumab Phase 1
13th Sep 20181:05 pmRNSPDMR Dealing
12th Sep 20187:00 amRNSPDMR dealings
11th Sep 20187:00 amRNSPDMR Dealing
24th Aug 20187:00 amRNSPDMR Dealing
21st Aug 20187:00 amRNSPDMR dealings
20th Aug 20187:00 amRNSPDMR Dealing
17th Aug 20187:00 amRNSPDMR Dealing
16th Aug 20189:00 amRNSFiling of Investigational New Drug application
27th Jul 20187:00 amRNSUS Registration Statement for Proposed Offering
25th Jun 201810:49 amRNSResult of AGM
7th Jun 20187:01 amRNSAppointment of Broker
7th Jun 20187:00 amRNSFinal Results
1st Jun 20187:00 amRNSNotice of AGM
23rd May 20184:40 pmRNSSecond Price Monitoring Extn
23rd May 20184:35 pmRNSPrice Monitoring Extension
16th May 20187:00 amRNSMilciclib Phase 2a Trial - Tolerability Update
1st May 20183:00 pmRNSGrant of Options - Director Dealing
27th Apr 20187:00 amRNSIssue of Equity
19th Apr 20187:00 amRNSSubscription
16th Apr 20187:25 amRNSLicense Agreement
9th Apr 20188:25 amRNSPresentation at ASCO 3 June 2018
5th Apr 20187:00 amRNSAppointment of Broker
4th Apr 20187:00 amRNSAppointment of Director
5th Mar 20187:00 amRNSPlacing to raise £600,000 and issue of equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.